Kura Oncology, Inc.
Kura Oncology is dedicated to realizing the promise of precision medicines to help cancer patients lead better, longer lives. They focus on developing targeted, well-tolerated treatments that expand patient populations and prevent tumor resistance, aiming to redefine patient outcomes through scientific innovation.
Industries
Nr. of Employees
medium (51-250)
Kura Oncology, Inc.
Patents
Macrocyclic compounds and compositions, and methods of preparing and using the same
US-12018011-B2
View DetailsMethods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US-11672774-B2
View Details
Macrocyclic compounds and compositions, and methods of preparing and using the same
US-12018011-B2
View DetailsMethods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US-11672774-B2
View DetailsProducts
Investigational menin inhibitor (oral small‑molecule)
An investigational small‑molecule menin inhibitor developed for the treatment of genetically defined acute leukemias and evaluated as monotherapy and in combinations with standard regimens or targeted agents.
Farnesyl transferase inhibitor programs (first‑ and next‑generation FTIs)
Programs evaluating farnesyl transferase inhibitors as monotherapy and in combinations for head and neck squamous cell carcinoma and other solid tumors, including next‑generation FTIs in dose‑escalation studies.
Investigational menin inhibitor (oral small‑molecule)
An investigational small‑molecule menin inhibitor developed for the treatment of genetically defined acute leukemias and evaluated as monotherapy and in combinations with standard regimens or targeted agents.
Farnesyl transferase inhibitor programs (first‑ and next‑generation FTIs)
Programs evaluating farnesyl transferase inhibitors as monotherapy and in combinations for head and neck squamous cell carcinoma and other solid tumors, including next‑generation FTIs in dose‑escalation studies.
Services
Design, sponsor and operationally manage multicenter Phase 1–2 oncology trials including dose‑escalation and combination cohorts.
Evaluation and coordination of requests for investigational drug access outside clinical studies.
Design, sponsor and operationally manage multicenter Phase 1–2 oncology trials including dose‑escalation and combination cohorts.
Evaluation and coordination of requests for investigational drug access outside clinical studies.
Expertise Areas
- Precision oncology
- Early‑phase clinical development
- Biomarker‑driven drug development
- Combination therapy development
Key Technologies
- Small‑molecule oncology drug discovery (menin and FTI mechanisms)
- Molecular diagnostic testing for somatic mutations (tumor genotyping)
- PK/PD assessment
- Dose‑escalation and adaptive trial design
News & Updates
Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed/Refractory NPM1-Mutated AML
Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed/Refractory NPM1-Mutated AML